Adjuvant radiotherapy in the era of new peri-operative systemic treatments for surgically resected non-small-cell lung cancer: where do we stand?

ABSTRACT: The role of post-operative radiotherapy (PORT) in radically resected non-small-cell lung cancer (NSCLC) remains a topic of debate, particularly in pN2 disease. While phase III trials like PORT-C and LungART have demonstrated a significant reduction in mediastinal recurrence, they have failed to show improvements in disease-free survival (DFS) or overall survival (OS), raising concerns about increased cardiopulmonary toxicity. The rapid integration of chemo-immunotherapy and targeted therapies into peri-operative treatment has reshaped the NSCLC landscape, lowering the risk of distant failure and overall mortality while leaving local recurrence rates largely unchanged. Striking results from trials on immune checkpoint inhibitors and tyrosine kinase inhibitors in early-stage NSCLC highlight

SUBMITTER: Ogliari FR 

PROVIDER: S-EPMC12432660 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature